KLRS

Kalaris Therapeutics, Inc. NGM · KLRS

$4.38 -0.23 (-4.99%)

Neutral · -0.36σ Grade A

+ Compare Open in Sniper

Mkt cap $0.1B

P/E —

Day $4.30 – $6.25

52wk $3.90 – $11.22

Avg vol 0.3M

Beta —

Div yld —

Next earnings —

Quick read

Plain English

Kalaris Therapeutics Stock Summary

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company's primary asset is TH103, an experimental drug targeting neovascular age-related macular degeneration (nAMD), currently in Phase 1b/2 clinical trials. As a development-stage biotech firm in the healthcare sector, the company is working to commercialize therapies for prevalent eye conditions caused by abnormal blood vessel growth in the retina.

The stock has been experiencing recent weakness, closing at $4.38 per share after declining 4.99% in the latest session. This price sits closer to the lower end of its 52-week trading range of $3.90 to $11.22, indicating significant pullback from its yearly high. The technical picture shows the stock in neutral territory overall, trading just slightly below its recent average. However, the RSI reading of 19.9 suggests the stock has entered oversold conditions based on its very short-term price momentum.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC3 upper (deep stretch), -0.37 ATR from EMA21 — doji

Long —

score 18 · tech 18 / 80 · support 0 / 20

above KC1 lower, -0.37 ATR from EMA21 · doji

· Doji — indecision, watch for reversal
· Volume 17.8x avg (no candle alignment)

How this grade was earned

total 18 pts

Cycle position 6

Candle signal 6

Volume 3

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short A

score 55 · tech 55 / 80 · support 0 / 20

KC3 upper (deep stretch), -0.37 ATR from EMA21 · doji

ℹ️ Deep stretch (KC3): stop is set wider to avoid a whipsaw, so the reward/risk reads lower (~1R) by design — not a worse trade.

· KC3 upper stretch — deepest mean-reversion tier
· Doji — indecision, watch for reversal
· Stochastic bear cross

How this grade was earned

total 55 pts

Cycle position 30

Candle signal 6

Momentum 3

Volume 10

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Candle-size grades

tap a size to open that chart

15mB30m–1h–4h–1DA

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 45), the trend is quiet (ADX 14), and trading is unusually heavy at 17.8× normal volume.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI

0–100 · <30 oversold

Trend strength · ADX

>25 = strong trend

Volume vs avg

17.82×

1× = average

Stretch from avg

-0.4 ATR

− below · + above

Zone touches

tests of this zone

Suggested hold

5–60

bars (≈ days)

Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Debt / equity

0.02

lower = less leveraged

P/E ratio

-2.7

price ÷ yearly profit

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Verdict

Unknown

Accounting quality Adequate

✓ More cash than debt
✓ Current ratio 12.23 (antifragile)
✓ Debt/equity 0.54 (antifragile)

⚠ Negative retained earnings

Key statistics

All statistics →

KLRS is a $104 million company, the stock is trading near the bottom of its 52-week range.

Mkt cap $0.1B

P/E ttm —

Fwd P/E -2.7

Beta —

Day range $4.30 – $6.25

52w range $3.90 – $11.22

Avg vol 0.3M

RSI(2) 19.9

ROE -66.6%

Net mgn —

FCF mgn —

Debt/Eq 0.02

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn —

52-week range · today's price

$3.90$11.22

More on KLRS

Options idea

See more →

ITM PUT $5 2026-09-18 · 63d

~$0.63

OTM PUT $4 2026-09-18 · 63d

~$0.06

ITM tracks the stock · OTM is cheaper / more leverage. Model-priced — verify the live chain. As of 8h ago (2026-07-17 20:47 UTC).

Earnings

See more →

Last reported: 2026-05-12
EPS (act / est): -0.46 / -0.52
Surprise: +12.1%
Next report: 2025-08-07

About

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatmen…